Literature DB >> 8027305

Accuracy and cost of antibiotic susceptibility testing of mixed morphotypes of Pseudomonas aeruginosa.

G L Morlin1, D L Hedges, A L Smith, J L Burns.   

Abstract

Chronic Pseudomonas aeruginosa colonization of the lower respiratory tract of patients with cystic fibrosis frequently results in pulmonary exacerbations requiring treatment with antimicrobial agents. Multiple morphotypes with different antibiotic susceptibilities are often isolated from a single sputum sample. Determination of MICs of antibiotics for each sputum morphotype is used to guide therapy but is time-consuming and expensive. We explored an alternative assay for determining MICs for all P. aeruginosa morphotypes cultured from a homogenized sputum sample. We sought correlations of those MICs with the MIC for the most resistant morphotypes tested separately. The MICs determined for a mixture of morphotypes correctly predicted the highest MICs (+/- one dilution) determined for isolated morphotypes 73.5% of the time. The MIC for the mixed morphotypes correctly predicted susceptibility in 90.4% of samples. In contrast, determination of the MIC for the mixture of morphotypes correctly predicted resistance in only 57.0%. For sputa containing susceptible isolates, testing the mixed culture may provide adequate susceptibility data with significant laboratory time and cost savings. However, for sputa with resistant strains, the traditional method of testing isolated morphotypes should still be used.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8027305      PMCID: PMC267174          DOI: 10.1128/jcm.32.4.1027-1030.1994

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  7 in total

1.  Mixed morphotype susceptibility testing of Pseudomonas aeruginosa from patients with cystic fibrosis.

Authors:  W M Dunne; M J Chusid
Journal:  Diagn Microbiol Infect Dis       Date:  1987-02       Impact factor: 2.803

2.  Mixed-morphotype broth microdilution susceptibility testing of Pseudomonas aeruginosa from cystic fibrosis patients.

Authors:  K G Van Horn
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

3.  Selective media for the quantitation of bacteria in cystic fibrosis sputum.

Authors:  K Wong; M C Roberts; L Owens; M Fife; A L Smith
Journal:  J Med Microbiol       Date:  1984-04       Impact factor: 2.472

4.  Selective and differential medium for recovery of Pseudomonas cepacia from the respiratory tracts of patients with cystic fibrosis.

Authors:  D F Welch; M J Muszynski; C H Pai; M J Marcon; M M Hribar; P H Gilligan; J M Matsen; P A Ahlin; B C Hilman; S A Chartrand
Journal:  J Clin Microbiol       Date:  1987-09       Impact factor: 5.948

Review 5.  Microbiology of airway disease in patients with cystic fibrosis.

Authors:  P H Gilligan
Journal:  Clin Microbiol Rev       Date:  1991-01       Impact factor: 26.132

6.  Early bacteriologic, immunologic, and clinical courses of young infants with cystic fibrosis identified by neonatal screening.

Authors:  S H Abman; J W Ogle; R J Harbeck; N Butler-Simon; K B Hammond; F J Accurso
Journal:  J Pediatr       Date:  1991-08       Impact factor: 4.406

7.  Antimicrobial susceptibilities of rough, smooth, and mucoid colony types of Pseudomonas isolated from cystic fibrosis patients.

Authors:  B A Maybury; J Blessing-Moore; S A deWit; N J Lewiston; A S Yeager
Journal:  Antimicrob Agents Chemother       Date:  1979-03       Impact factor: 5.191

  7 in total
  8 in total

Review 1.  Laboratory aspects of management of chronic pulmonary infections in patients with cystic fibrosis.

Authors:  Melissa B Miller; Peter H Gilligan
Journal:  J Clin Microbiol       Date:  2003-09       Impact factor: 5.948

2.  Evaluation of reference dilution test methods for antimicrobial susceptibility testing of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis.

Authors:  L Saiman; J L Burns; S Whittier; J Krzewinski; S A Marshall; R N Jones
Journal:  J Clin Microbiol       Date:  1999-09       Impact factor: 5.948

Review 3.  Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients.

Authors:  Axel Dalhoff
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

4.  Pseudomonas aeruginosa clinical isolates: serotypes, resistance phenotypes and plasmid profiles.

Authors:  M Millesimo; G de Intinis; M G Chirillo; T Musso; D Savoia
Journal:  Eur J Epidemiol       Date:  1996-04       Impact factor: 8.082

5.  Evaluation of the Merlin, Micronaut system for automated antimicrobial susceptibility testing of Pseudomonas aeruginosa and Burkholderia species isolated from cystic fibrosis patients.

Authors:  S Häussler; S Ziesing; G Rademacher; L Hoy; H Weissbrodt
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-07-25       Impact factor: 3.267

6.  Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents.

Authors:  T L Pitt; M Sparrow; M Warner; M Stefanidou
Journal:  Thorax       Date:  2003-09       Impact factor: 9.139

7.  Recombination is a key driver of genomic and phenotypic diversity in a Pseudomonas aeruginosa population during cystic fibrosis infection.

Authors:  Sophie E Darch; Alan McNally; Freya Harrison; Jukka Corander; Helen L Barr; Konrad Paszkiewicz; Stephen Holden; Andrew Fogarty; Shanika A Crusz; Stephen P Diggle
Journal:  Sci Rep       Date:  2015-01-12       Impact factor: 4.379

8.  Global fluoroquinolone resistance epidemiology and implictions for clinical use.

Authors:  Axel Dalhoff
Journal:  Interdiscip Perspect Infect Dis       Date:  2012-10-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.